Supplementary Figure S1 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy | Synapse
October 17, 2025Open Access
Supplementary Figure S1 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
Key Points
Blinatumomab treatment demonstrates a structured approach in the consolidation phase of therapy for leukemia.
The E1910 trial design includes a defined randomization scheme, providing clarity on the therapy phases involved.
Chemotherapy remains a critical component in managing B-cell precursor acute lymphoblastic leukemia during treatment.
Key insights into the therapy structure can enhance future research on leukemia treatment protocols.
Abstract
Figure S1 shows the E1910 Trial Design, including randomization scheme and phases of therapy.